#nubeka

Long-Term Darolutamide Displays Favorable Safety Profile in Patients With mCRPC

Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug. Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with darolutamide (Nubeqa) for more than 4 years tolerated well the adverse effects (AEs) of the drug. These extended darolutamide safety and tolerability results…